Department of Biomedical Engineering, School of Medicine, School of Engineering, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
Institute of Molecular Cardiology, University of Louisville, Louisville, Kentucky, USA.
J Am Coll Cardiol. 2021 Nov 23;78(21):2092-2105. doi: 10.1016/j.jacc.2021.09.019.
This paper aims to provide an important update on the recent preclinical and clinical trials using cell therapy strategies and engineered heart tissues for the treatment of postinfarction left ventricular remodeling and heart failure. In addition to the authors' own works and opinions on the roadblocks of the field, they discuss novel approaches for cardiac remuscularization via the activation of proliferative mechanisms in resident cardiomyocytes or direct reprogramming of somatic cells into cardiomyocytes. This paper's main mindset is to present current and future strategies in light of their implications for the design of future patient trials with the ultimate objective of facilitating the translation of discoveries in regenerative myocardial therapies to the clinic.
本文旨在提供细胞治疗策略和工程化心脏组织在治疗心肌梗死后左心室重构和心力衰竭方面的最新临床前和临床试验的重要更新。除了作者自己的工作和对该领域障碍的看法外,他们还讨论了通过激活驻留心肌细胞的增殖机制或直接将体细胞重编程为心肌细胞来实现心脏再肌化的新方法。本文的主要思路是根据它们对未来患者试验设计的影响来呈现当前和未来的策略,最终目标是促进再生心肌治疗发现向临床的转化。